Viscoelastic testing in benign hematologic disorders: Clinical perspectives and future implications of point-of-care testing to assess hemostatic competence.
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
01
05
2020
revised:
04
09
2020
accepted:
05
09
2020
entrez:
22
10
2020
pubmed:
23
10
2020
medline:
14
8
2021
Statut:
ppublish
Résumé
Viscoelastic tests (VETs) have been used routinely for liver transplantation, cardiac surgery, and trauma, but only recently have found clinical utility in benign hematologic disorders. Therefore, guidelines for diagnosis and treatment of these disorders based on viscoelastic variables have been adapted from the existing transplant, cardiothoracic surgery, and trauma resuscitation literature. As a result, diagnostic and therapeutic strategies for benign hematologic disorders utilizing VETs are not uniform. Accordingly, even though there has been a recent increase in the utilization of VET for the diagnosis and treatment of such disorders, the literature is still in its early stages. Analysis of point-of-care viscoelastic tracings from benign hematologic disorders has the potential to allow prompt recognition of disease and to guide patient-specific intervention. Here we present a review describing the application of VETs to benign hematologic disorders.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S101-S121Informations de copyright
© 2020 AABB.
Références
Ostrowski SR, Berg RM, Windelov NA, et al. Discrepant fibrinolytic response in plasma and whole blood during experimental endotoxemia in healthy volunteers. PLoS One. 2013;8(3):e59368.
Curry NS, Davenport R, Pavord S, et al. The use of viscoelastic haemostatic assays in the management of major bleeding: a British Society for Haematology Guideline. Br J Haematol. 2018;182(6):789-806.
Johansson P, Stensballe J, Ostrowski S. Shock induced endotheliopathy (SHINE) in acute critical illness-a unifying pathophysiologic mechanism. Crit Care. 2017;21(1):25.
Levi M, Hunt BJ. A critical appraisal of point-of-care coagulation testing in critically ill patients. J Thromb Haemost. 2015;13(11):1960-1967.
Levi M, Sivapalaratnam S. Hemostatic abnormalities in critically ill patients. Intern Emerg Med. 2015;10(3):287-296.
Raffini L, Witmer C. Pediatric transplantation: managing bleeding. J Thromb Haemost. 2015;13(Suppl 1):S362-S369.
Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg. 1999;88(2):312-319.
Hincker A, Feit J, Sladen RN, Wagener G. Rotational thromboelastometry predicts thromboembolic complications after major non-cardiac surgery. Crit Care. 2014;18(5):549.
Walsh M, Fritz S, Hake D, et al. Targeted thromboelastographic (TEG) blood component and pharmacologic hemostatic therapy in traumatic and acquired coagulopathy. Curr Drug Targets. 2016;17(8):954-970.
Holcomb J, Minei K, Scerbo M, et al. Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients. Ann Surg. 2012;256(3):476-486.
Moore EE, Moore HB, Chapman MP, Gonzalez E, Sauaia A. Goal-directed hemostatic resuscitation for trauma induced coagulopathy: maintaining homeostasis. J Trauma Acute Care Surg. 2018;84(6S Suppl 1):S35-S40.
Schmidt AE, Israel AK, Refaai MA. The utility of thromboelastography to guide blood product transfusion: an ACLPS critical review. Am J Clin Pathol. 2019;152(4):407-422.
Snegovskikh D, Souza D, Walton Z, et al. Point-of-care viscoelastic testing improves the outcome of pregnancies complicated by severe postpartum hemorrhage. J Clin Anesth. 2018;44:50-56.
Solomon C, Collis RE, Collins PW. Haemostatic monitoring during postpartum haemorrhage and implications for management. Br J Anaesth. 2012;109(6):851-863.
Collis RE, Collins PW. Haemostatic management of obstetric haemorrhage. Anaesthesia. 2015;70(Suppl 1):78-86, e27-78.
Kang YG, Martin DJ, Marquez J, et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg. 1985;64(9):888-896.
Enriquez LJ, Shore-Lesserson L. Point-of-care coagulation testing and transfusion algorithms. Br J Anaesth. 2009;103(Suppl I):i14-i22.
Wikkelso A, Wetterslev J, Moller AM, Afshari A. Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2017;72(4):519-531.
Hunt H, Stanworth S, Curry N, et al. Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for trauma-induced coagulopathy in adult trauma patients with bleeding. Cochrane Database Syst Rev. 2015;2015(2):CD010438.
Schöchl H, Nienaber U, Maegele M, et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care. 2011;15(2):R83.
Schochl H, Cotton B, Inaba K, et al. FIBTEM provides early prediction of massive transfusion in trauma. Crit Care. 2011;15(6):R265.
Görlinger K, Dirkmann D, Hanke AA, et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery. Surv Anesthesiol. 2012;56(4):163-164.
Galster H, Kolb G, Kohsytorz A, Seidlmayer C, Paal V. The pre-, peri-, and postsurgical activation of coagulation and the thromboembolic risk for different risk groups. Thromb Res. 2000;100(5):381-388.
Xu M, Luo L, Du M, Tang L, Hu Y, Mei H. Fibrinogen levels are associated with bleeding in patients with primary immune thrombocytopenia. Platelets. 2020;31(6):763-770.
Me L, Li Y, Xue F, et al. Application of immature platelet fraction absolute immature platelet fraction and thrombelastograph on assessment of bleeding risk in patients with immune thrombocytopenia. Zhonghua Xue Ye Xue Za Zhi. 2015;36(9):759-764.
Larsen OH, Stentoft J, Radia D, Ingerslev J, Sørensen B. Combination of recombinant factor VII a and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. Br J Haematol. 2013;160(2):228-236.
Gunduz E, Akay OM, Bal C, Gulbas Z. Can thrombelastography be a new tool to assess bleeding risk in patients with idiopathic thrombocytopenic purpura? Platelets. 2011;22(7):516-520.
Sanz RJ, Manzano EM, Bello IF, et al. Platelet apoptosis and PAI-1 are involved in the pro-coagulant state of immune thrombocytopaenia patients treated with thrombopoietin receptor agonists. Thromb Haemost. 2019;119(04):645-659.
Alvarez-Roman MT, Fernandez-Bello I, Jimenez-Yuste V, et al. Procoagulant profile in patients with immune thrombocytopenia. Br J Haematol. 2016;175(5):925-934.
Kim C, Park SS, Davey JR. Tranexamic acid for the prevention and management of orthopedic surgical hemorrhage: current evidence. J Blood Med. 2015;6:239-244.
Kim WH, Park JB, Jung CW, Kim GS. Rebalanced hemostasis in patients with idiopathic thrombocytopenic purpura. Platelets. 2015;26(1):38-42.
Misgav M, Shenkman B, Budnik I, Einav Y, Martinowitz U. Differential roles of fibrinogen and von Willebrand factor on clot formation and platelet adhesion in reconstituted and immune thrombocytopenia. Anesth Analg. 2011;112(5):1034-1040.
Greene LA, Chen S, Seery C, Imahiyerobo AM, Bussel JB. Beyond the platelet count: immature platelet fraction and thromboelastometry correlate with bleeding in patients with immune thrombocytopenia. Br J Haematol. 2014;166(4):592-600.
Kim SY, Gu JY, Yoo HJ, et al. Benefits of thromboelastography and thrombin generation assay for bleeding prediction in patients with thrombocytopenia or hematologic malignancies. Ann Lab Med. 2017;37(6):484-493.
Umakanthan JM, Dhakal P, Gundabolu K, Kallam A, Almquist DR, Bhatt VR. Initial management of immune thrombocytopaenia in adults based on risk stratification. Postgrad Med J. 2019;95(1128):558-562.
Stentoft J. ITP: from idiopathic purpura to immune thrombocytopenia and back. Br J Haematol. 2016;175(5):755-756.
Akay OM, Sahin DG, Andic N, et al. The utility of thromboelastometry in prophylactic platelet transfusion for hematological malignancies. Transfus Apher Sci. 2015;53(1):64-68.
Ismael F, van der Meer J, de Wolf JTM, Kuizenga K, Aarts LP, Hendriks HG. Thromboelastographic evaluation of recombinant factor VIIa in a child with Glanzmann's thrombasthenia. Anesth Analg. 2006;103(3):791-792.
Topal A, Kılıçaslan A, Erol A, Çankaya B, Otelcioğlu Ş. Anaesthetic management with thromboelastography in a patient with Glanzmann thrombasthenia. Turk J Anaesthesiol Reanim. 2014;42(4):227.
Callaghan MU, Chitlur MB, Lusher JM, Rapjurkkar M, Fleming P. Thromboelastogram platelet mapping accurately predicts bleeding phenotype in Glanzmann thrombasthenia. Blood. 2008;112(11):4560.
Castellino FJ, Liang Z, Davis PK, et al. Abnormal whole blood thrombi in humans with inherited platelet receptor defects. PLoS One. 2012;7(12):e52878.
Ahammad J, Kamath A, Shastry S, Chitlur M, Kurien A. Clinico-hematological and thromboelastographic profiles in glanzmann's thrombasthenia. Blood Coagul Fibrinolysis. 2020;31(1):29-34.
Monte S, Lyons G. Peripartum management of a patient with Glanzmann's thrombasthenia using Thrombelastograph®. Br J Anaesth. 2002;88(5):734-738.
Zia A, Chitlur M, Rajpurkar M, et al. Thromboelastography identifies children with rare bleeding disorders and predicts bleeding phenotype. Haemophilia. 2015;21(1):124-132.
Male C, Koren D, Eichelberger B, Kaufmann K, Panzer S. Monitoring survival and function of transfused platelets in Glanzmann thrombasthenia by flow cytometry and thrombelastography. Vox Sang. 2006;91(2):174-177.
Lak M, Scharling B, Blemings A, et al. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram. Haemophilia. 2008;14(1):103-110.
Barg AA, Hauschner H, Misgav M, et al. A novel approach using ancillary tests to guide treatment of Glanzmann thrombasthenia patients undergoing surgical procedures. Blood Cells Mol Dis. 2018;72:44-48.
Grassetto A, Fullin G, Lazzari F, et al. Perioperative ROTEM and ROTEMplatelet monitoring in a case of Glanzmann's thrombasthenia. Blood Coagul Fibrinolysis. 2017;28(1):96-99.
Bakdash S, Lyons JM, Bastacky SI, et al. Management of persistent gastric bleeding in a patient with Glanzmann's thrombasthenia. Am J Hematol. 2008;83(5):411-415.
Kostopanagiotou G, Siafaka I, Sikiotis C, Smyrniotis V. Anesthetic and perioperative management of a patient with Bernard-Soulier syndrome. J Clin Anesth. 2004;16(6):458-460.
Palsson R, Vidarsson B, Gudmundsdottir BR, et al. Complementary effect of fibrinogen and rFVIIa on clotting ex vivo in Bernard-Soulier syndrome and combined use during three deliveries. Platelets. 2014;25(5):357-362.
Boppana SS, Hall B, Beaujon A, Tumin D, Tobias JD. Anesthetic care of a patient with Bernard-Soulier syndrome for posterior spinal fusion. J Med Case. 2018;9(10):341-344.
Rodseth RN. The perioperative management of Bernard-Soulier syndrome: a case report and review of the role of perioperative factor VIIa. South Afr J Anaesth Analg. 2010;16(6):37-39.
Johansson PI, Stensballe J, Oliveri R, Wade CE, Ostrowski SR, Holcomb JB. How I treat patients with massive hemorrhage. Blood. 2014 Nov 13;124(20):3052-8.
Lang T, Johanning K, Metzler H, et al. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg. 2009;108(3):751-758.
Hill QA. Immune thrombocytopenia-in defence of the platelet count. Br J Haematol. 2018;182(1):128-130.
Cesar JM, Vecino AM. Survival and function of transfused platelets. Studies in two patients with congenital deficiencies of platelet membrane glycoproteins. Platelets. 2009;20(3):158-162.
Genét GF, Ostrowski SR, Sørensen AM, Johansson PI. Detection of tPA-induced hyperfibrinolysis in whole blood by RapidTEG, KaolinTEG, and functional fibrinogenTEG in healthy individuals. Clin Appl Thromb Hemost. 2012;18(6):638-644.
National Heart, Lung, and Blood Institute. NHLBI Von Willebrand Disease Expert Panel. The diagnosis, evaluation and management of von Willebrand disease. NIH publication no. 08-5832. Bethesda, Md.: U.S. Department of Health and Human Services; December 2007. http://www.nhlbi.nih.gov/guidelines/vwd/index.htm.
Regling K, Kakulavarapu S, Thomas R, Hollon W, Chitlur MB. Utility of thromboelastography for the diagnosis of von Willebrand disease. Pediatr Blood Cancer. 2019;66(7):e27714.
Topf HG, Weiss D, Lischetzki G, Strasser E, Rascher W, Rauh M. Evaluation of a modified thromboelastography assay for the screening of von Willebrand disease. Thromb Haemost. 2011;105(6):1091-1099.
Toukh M, Ozelo M, Angelillo-Scherrer A, Othman M. A novel use of thromboelastography in type 2B von Willebrand disease. Int J Lab Hematol. 2013;35(6):e11-e14.
Guzman-Reyes S, Osborne C, Pivalizza EG. Thrombelastography for perioperative monitoring in patients with von Willebrand disease. J Clin Anesth. 2012;24(2):166-167.
Schmidt D, Majeed A, Bruzelius M, Odeberg J, Holmström M, Ågren A. A prospective diagnostic accuracy study evaluating rotational thromboelastometry and thromboelastography in 100 patients with von Willebrand disease. Haemophilia. 2017;23(2):309-318.
Boyd EZ, Riha K, Escobar MA, Pivalizza EG. Thrombelastograph platelet mapping in a patient with von Willebrand disease who was treated with Humate-P. J Clin Anesth. 2011;23(7):600.
Topf H-G, Strasser E, Breuer G, Rascher W, Rauh M, Fahlbusch F. Closing the gap - detection of clinically relevant von Willebrand disease in emergency settings through an improved algorithm based on rotational thromboelastometry. BMC Anesthesiol. 2019;19(1):10.
Ramiz S, Hartmann J, Young G, Escobar MA, Chitlur M. Clinical utility of viscoelastic testing (TEG and ROTEM analyzers) in the management of old and new therapies for hemophilia. Am J Hematol. 2019;94(2):249-256.
Sørensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost. 2004;2(1):102-110.
Bolton-Maggs PHB. The rare inherited coagulation disorders. Pediatr Blood Cancer. 2013;60(S1):S37-S40.
Chitlur M, Warrier I, Rajpurkar M, et al. Thromboelastography in children with coagulation factor deficiencies. Br J Haematol. 2008;142(2):250-256.
Viuff D, Andersen S, Sørensen BB, Lethagen S. Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven®) therapy in haemophilia a patients. Thromb Res. 2010;126(2):144-149.
Tarandovskiy ID, Balandina AN, Kopylov KG, et al. Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics. Thromb Res. 2013;131(6):e274-e280.
Aghighi S, Riddell A, Lee CA, Brown SA, Tuddenham E, Chowdary P. Global coagulation assays in hemophilia A: a comparison to conventional assays. Res Pract Thromb Haemost. 2020;4(2):298-308.
van Veen JJ, Gatt A, Bowyer AE, Cooper PC, Kitchen S, Makris M. Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A. Thromb Res. 2009;123(6):895-901.
Bowyer AE, Van Veen JJ, Goodeve AC, Kitchen S, Makris M. Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A. Haematologica. 2013;98(12):1980-1987.
Nogami K. The utility of thromboelastography in inherited and acquired bleeding disorders. Br J Haematol. 2016;174(4):503-514.
Yada K, Nogami K, Wakabayashi H, Fay PJ, Shima MJT. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X. Thromb Haemost. 2013;109(06):1007-1015.
Yada K, Nogami K, Shida Y, Takeyama M, Kasai R, Shima M. Enhanced global hemostatic potentials with a bispecific antibody to factors IXa and X (ACE910) in the whole blood by rotation thromboelastometry (ROTEM). Washington, DC: American Society of Hematology, 2015.
Al Hawaj MA, Martin EJ, Venitz J, et al. Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia. 2013;19(3):409-414.
Dargaud Y, Lambert T, Trossaert M. New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors. Haemophilia. 2008;14:20-27.
Fernandez-Bello I, Stenmo C, Butta N, Lind V, Ezban M, Jimenez-Yuste V. The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B. Haemophilia. 2017;23(6):868-876.
Sørensen B, Ingerslev J. Platelet infusion supports recombinant factor VIIa in a patient with severe haemophilia A and inhibitor-clinical outcome and laboratory observations. Thromb Haemost. 2010;103(06):1275-1276.
Dunkley S, Yang K. The use of combination FEIBA and rFVIIa bypassing therapy, with TEG profiling, in uncontrollable bleeding associated with acquired haemophilia A. Haemophilia. 2009;15(3):828-830.
Young G, Blain R, Nakagawa P, Nugent DJH. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia. 2006;12(6):598-604.
Shima M, Matsumoto T, Ogiwara KJH. New assays for monitoring haemophilia treatment. Haemophilia. 2008;14:83-92.
Fisher C, Mo A, Warrillow S, Smith C, Jones D. Utility of thromboelastography in managing acquired Factor VIII inhibitor associated massive haemorrhage. Anaesth Intens care. 2013;41(6):799-803.
Pivalizza EG, Escobar MA. Thrombelastography-guided factor VIIa therapy in a surgical patient with severe hemophilia and factor VIII inhibitor. Anesth Analg. 2008;107(2):398-401.
Qi X, Zhao Y, Li K, Fan L, Hua B. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors. Blood Coagul Fibrinolysis. 2014;25(7):754-760.
Schneiderman J, Rubin E, Nugent D, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia. 2007;13(3):244-248.
Spiezia L, Meneghetti L, Dalla Valle F, et al. Potential role of thrombelastography in the monitoring of acquired factor VIII inhibitor hemophilia A: report on a 78-year-old woman with life-threatening bleedings. Clin Appl Thromb Hemost. 2009;15(4):470-476.
Furukawa S, Nogami K, Ogiwara K, Yada K, Minami H, Shima M. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry. J Thromb Haemost. 2015;13(7):1279-1284.
Salinas V, Carmona R, Mohammed B, Martin E, Brophy D, Young G. Is some better than none: are TEG and TGA profiles different in severe FVIII-deficient patients with inhibitors? Haemophilia. 2015;21(3):398-404.
Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thrombo Haemost. 1997;77(06):1113-1119.
Parameswaran R, Shapiro A, Gill J, Kessler C, Investigators HR. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia. 2005;11(2):100-106.
Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546-551.
Nogami K, Matsumoto T, Yada K, et al. Factor (F) VIII/VII a enhances global haemostatic function in the co-presence of bypassing agents and FVIII among patients with haemophilia A with inhibitor. Br J Haematol. 2018;181(4):528-536.
Young G, Sørensen B, Dargaud Y, Negrier C, Brummel-Ziedins K, Key NS. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood. 2013;121(11):1944-1950.
Young G, Ebbesen LS, Viuff D, et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis. 2008;19(4):276-282.
Pan-Petesch B, Laguna P, Mital A, et al. Single-dose (270 μg kg− 1) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres. Haemophilia. 2009;15(3):760-765.
Tran H, Sørensen B, Bjørnsen S, Pripp A, Tjønnfjord G, Andre HP. Monitoring bypassing agent therapy-a prospective crossover study comparing thromboelastometry and thrombin generation assay. Haemophilia. 2015;21(2):275-283.
Astermark J, Rocino A, Von Depka M, et al. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia. 2007;13(1):38-45.
Hayashi T, Tanaka I, Shima M, et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. 2004;10(4):397-400.
Przkora R, Euliano T, Roussos-Ross K, Zumberg M, Robicsek S. Labor and delivery in a patient with hemophilia B. Int J Obstet Anesth. 2011;20(3):250-253.
De Pietri L, Masetti M, Montalti R, et al. Use of recombinant factor IX and thromboelastography in a patient with hemophilia B undergoing liver transplantation: a case report. Transplant Proc. 2008;40(6):2077-2079.
De Pietri L, Montalti R, Begliomini B, et al. Thromboelastographic changes in liver and pancreatic cancer surgery: hypercoagulability, hypocoagulability or normocoagulability? Eur J Anaesthesiol. 2010;27(7):608-616.
Nummi V, Jouppila A, Lassila R. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity. Int J Lab Hematol. 2017;39(4):359-368.
Spiezia L, Radu C, Campello E, et al. Whole blood rotation thromboelastometry (ROTEM®) in nine severe factor V deficient patients and evaluation of the role of intraplatelets factor V. 2012;18(3):463-468.
Tran H, Tjønnfjord G, Holme P. Use of thromboelastography and thrombin generation assay to predict clinical phenotype in patients with severe FVII deficiency. Haemophilia. 2014;20(1):141-146.
Al Dieri R, Peyvandi F, Santagostino E, et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost. 2002;88(4):576-582.
Van Geffen M, Menegatti M, Loof A, et al. Retrospective evaluation of bleeding tendency and simultaneous thrombin and plasmin generation in patients with rare bleeding disorders. Haemophilia. 2012;18(4):630-638.
Zekavat OR, Haghpanah S, Dehghani J, Afrasiabi A, Peyvandi F, Karimi M. Comparison of thrombin generation assay with conventional coagulation tests in evaluation of bleeding risk in patients with rare bleeding disorders. Clin Appl Thromb Hemost. 2014;20(6):637-644.
Toret E, Ay Y, Karapinar TH, Oymak Y, Kavakli K, Vergin RC. Evaluation of Bleeding Phenotype of Inherited Factor VII Deficiency in Children With a Bleeding Assessment Tool and Global Assays. J Pediatr Hematol Oncol. 2020;42(6):e527-e530.
Greene L, Goldenberg N, Simpson M, et al. Use of global assays to understand clinical phenotype in congenital factor VII deficiency. Haemophilia. 2013;19(5):765-772.
O'Rourke N, Lee C, Kodali BS, Harnett M. Thromboelastographic® monitoring of the efficacy of recombinant factor VIIa administration in a parturient with factor VII deficiency. Can J Anesth. 2006;53(5):528-529.
Livnat T, Shenkman B, Kenet G, et al. Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG-correlation with thrombin generation and thromboelastometry. Blood Coagul Fibrinolysis. 2011;22(8):673-679.
O'Connell N, Riddell A, Pascoe G, Perry D, Lee C. Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency. Haemophilia. 2008;14(4):775-781.
Livnat T, Shenkman B, Martinowitz U, et al. The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency. Thromb Res. 2015;136(2):465-473.
Riddell A, Abdul-Kadir R, Pollard D, Tuddenham E, Gomez K. Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery. Thromb Haemost. 2011;106(3):521-527.
Kenet G, Lubetsky A, Luboshitz J, et al. Lower doses of rFVIIa therapy are safe and effective for surgical interventions in patients with severe FXI deficiency and inhibitors. Haemophilia. 2009;15(5):1065-1073.
Dirkmann D, Hanke A, Görlinger K, Peters J. Perioperative use of modified thrombelastography in factor XI deficiency: a helpful method to assess drug effects. Acta Anaesthesiol Scand. 2007;51(5):640-643.
Pike G, Cumming A, Thachil J, Hay C, Bolton-Maggs P, Burthem J. Evaluation of the use of rotational thromboelastometry in the assessment of FXI deficency. Haemophilia. 2017;23(3):449-457.
Pivalizza EG. Perioperative use of the Thrombelastograph® in patients with inherited bleeding disorders. J Clin Anesth. 2003;15(5):366-370.
Govers-Riemslag JW, Konings J, Cosemans JM, et al. Impact of deficiency of intrinsic coagulation factors XI and XII on ex vivo thrombus formation and clot lysis. TH Open. 2019;3(03):e273-e285.
Martinuzzo M, Barrera L, Altuna D, et al. Effects of factor XIII deficiency on thromboelastography. thromboelastography with calcium and streptokinase addition is more sensitive than solubility tests. Mediterr J Hematol Infect Dis. 2016;8(1):e2016037.
Hanke A, Elsner O, Görlinger K. Spinal anaesthesia and caesarean section in a patient with hypofibrinogenaemia and factor XIII deficiency. Anaesthesia. 2010;65(6):641-645.
Bouttefroy S, Meunier S, Jousselme E, Rugeri L. Benefits of thromboelastometry for monitoring replacement therapy in patients with severe inherited factor XIII deficiency: 3 illustrative cases. Haemophilia. 2019;25(5):e336-e338.
Lovejoy AE, Reynolds TC, Visich JE, et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood. 2006;108(1):57-62.
Wei A, Liao L, Xiang L, et al. Congenital dysfibrinogenaemia assessed by whole blood thromboelastography. Int J Lab Hematol. 2018;40(4):459-465.
Zhou J, Xin Y, Ding Q, et al. Thromboelastography predicts risks of obstetric complication occurrence in (hypo)dysfibrinogenemia patients under non-pregnant state. Clin Exp Pharmacol Physiol. 2016;43(2):149-156.
Young GA, Carmona R, Cano GV. Thromboelastography and thrombin generation assay in inherited afibrinogenemia. Haemophilia. 2018;24(6):e410-e416.
Treliński J, Pachniewska K, Matczak J, Nowak P, Robak M, Chojnowski K. Assessment of selected ROTEM parameters, kinetics of fibrinogen polymerization and plasmin amidolytic activity in patients with congenital fibrinogen defects. Adv Clin Exp Med. 2016;25(6):1255-1263.
Kalina U, Stöhr H-A, Bickhard H, et al. Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. Blood Coagul Fibrinolysis. 2008;19(8):777-783.
Ross C, Rangarajan S, Karimi M, et al. Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency. J Thromb Haemost. 2018;16(2):253-261.
Lissitchkov T, Madan B, Djambas Khayat C, et al. Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. J Thromb Haemost. 2020;18(4):815-824.
Peyvandi F. Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency. Thromb Res. 2009;124:S9-S11.
Sakimura S, Higashi M, Nanishi N, et al. Anesthetic management of a parturient with congenital afibrinogenemia undergoing cesarean section. Masui. 2012;61(12):1369-1372.
Li C, Wang D, Wei X. Perioperative management of pregnant women combined with congenital fibrinogen deficiency: four cases report and literature review. Beijing Da Xue Xue Bao Yi Xue Ban. 2018;50(5):932-936.
Jankun J, Skrzypczak-Jankun E. Bleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1. Exp Ther Med. 2010;1(4):575-577.
Kindell DG, Keck RW, Jankun J. Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid. Exp Ther Med. 2015;9(6):2339-2343.
Prabhakaran N, Laziuk K, Hammer RD. The utility of thromboelastography and tranexamic acid in plasminogen activator inhibitor deficiency during pregnancy: a rare case report. Blood Coagul Fibrinolysis. 2020;31(1):87-91.
Croteau SE, Cheng D, Cohen AJ, et al. Practical application of the Athndataset: evaluating uptake of extended half-life factor concentrates in patients with moderate and severe hemophilia. Blood. 2017;130(Suppl 1):23.
Misgav M, Mandelbaum T, Kassif Y, Berkenstadt H, Tamarin I, Kenet G. Thromboelastography during coronary artery bypass grafting surgery of severe hemophilia A patient-the effect of heparin and protamine on factor VIII activity. Blood Coagul Fibrinolysis. 2017;28(4):329-333.
Fogarty P, Mancuso M, Kasthuri R, et al. Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey. Haemophilia. 2015;21(5):589-597.
Tang M, Wierup P, Terp K, Ingerslev J, Sørensen B. Cardiac surgery in patients with haemophilia. Haemophilia. 2009;15(1):101-107.
Mumford AD, Ackroyd S, Alikhan R, et al. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2014;167(3):304-326.
Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood. 2015;125(13):2052-2061.
Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8(9):2063-2065.
Mariani G, Herrmann FH, et al. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. J Thromb Haemost. 2005;93(03):481-487.
Koopman K, Uyttenboogaart M, Hendriks HG, et al. Thromboelastography in patients with cerebral venous thrombosis. Thromb Res. 2009;124(2):185-188.
Bilen O, Loftis L, Teruya J. Severe thrombotic and bleeding complications in a baby with heterozygous factor V Leiden and acquired von Willebrand disease on ECMO. J Extra Corpor Technol. 2011;43(2):64.
Sadana N, Sparks L, Biggs D, Madamangalam A. Perioperative management of a parturient with antithrombin deficiency and the role of thromboelastography. Int J Obstet Anesth. 2012;21(3):287-288.
Miall FM, Deol PS, Barnes TA, et al. Coagulation status and complications of pregnancy. Thromb Res. 2005;115(6):461-467.
Goggs R, Wiinberg B, Kjelgaard-Hansen M, Chan DTVJ. Serial assessment of the coagulation status of dogs with immune-mediated haemolytic anaemia using thromboelastography. Vet J. 2012;191(3):347-353.
Tripodi A, Cappellini MD, Chantarangkul V, et al. Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. Haematologica. 2009;94(11):1520-1527.
Sirachainan N, Chuansumrit A, Kadegasem P, Sasanakul W, Wongwerawattanakoon P, Mahaklan L. Normal hemostatic parameters in children and young adults with α-thalassemia diseases. Thromb Res. 2016;146:35-42.
Turhan AB, Bör Ö, Akay OM, Akgün NAIJOH. Thromboelastometry profile in children with beta-thalassemia. Int J Hematol. 2014;99(4):407-412.
Natesirinilkul R, Charoenkwan P, Nawarawong W, et al. Hypercoagulable state as demonstrated by thromboelastometry in hemoglobin E/beta-thalassemia patients: association with clinical severity and splenectomy status. Thromb Res. 2016;140:125-131.
Özdemir ZC, Kar YD, Gündüz E, Bör Ö. Evaluation of the coagulation profile with rotational thromboelastometry in children with hereditary spherocytosis. J Pediatr Hematol Oncol. 2020;42(4):e195-e198.
Yee DL, Edwards RM, Mueller BU, Teruya J. Thromboelastographic and hemostatic characteristics in pediatric patients with sickle cell disease. Arch Pathol Lab Med. 2005;129(6):760-765.
Wijnberge M, Parmar K, Kesse-Adu R, Howard J, Cohen AT, Hunt BJJT. The utility of thromboelastography and thrombin generation in assessing the prothrombotic state of adults with sickle cell disease. Thromb Res. 2017;158:113-120.
Gupta S, Carmona R, Malvar J, Young G. Thromboelastographic Characterization of the Activated Clotting System in Children With Sickle Cell Trait or Sickle Cell Disease. Washington, DC: American Society of Hematology, 2016.
Wells AV, Zarkhin E, Weiner MM, Katz D. Heparin resistance due to an acquired antithrombin deficiency in a patient with sickle cell disease during a pregnancy complicated by bilateral pulmonary emboli: a case report. A A Pract. 2019;12(9):305-307.
Romano D, Craig H, Katz D. Management of cesarean delivery in a parturient with sickle cell disease. Int J Obstet Anesth. 2020;41:104-107.
Seregina E, Tsvetaeva N, Nikulina O, et al. Eculizumab effect on the hemostatic state in patients with paroxysmal nocturnal hemoglobinuria. Blood Cells Mol Dis. 2015;54(2):144-150.
Harahsheh Y, Ho K. Thromboelastometry and thromboelastography failed to detect hypercoagulability in thrombotic microangiopathy. Anaesth Intensive Care. 2016;44(4):520.
Kahr WH, Pluthero FG, Licht C. Complement factor H in human platelets: implications for atypical HUS. Blood. 2008;112(11):1833.
Knabl L, Berktold M, Hamad OA, et al. Shiga toxin 2a binds antithrombin and heparin, but does not directly activate platelets. Int J Med Microbiol. 2018;308(7):969-976.
Manook M, Kwun J, Burghuber C, et al. Thrombalexin: use of a cytotopic anticoagulant to reduce thrombotic microangiopathy in a highly sensitized model of kidney transplantation. Am J Transplant. 2017;17(8):2055-2064.
Nallarajah J, Sebastiampillai B, Jayanaga A, Jayasekara N. Dengue fever a rare cause of thrombotic thrombocytopenic purpura: a case report. J Postgrad Inst Med. 2019;6(1):1-3.
Bindi ML, Mazzoni A, Bisà M, et al. The challenges of diagnosing thrombotic thrombocytopenic purpura in the critically ill. A case report. Transfus Apher Sci. 2010;43(2):167-170.
Withana M, Rodrigo C, Gnanathasan A, Gooneratne L. Presumptive thrombotic thrombocytopenic purpura following a hump-nosed viper (Hypnale hypnale) bite: a case report. J Venom Anim Toxins Incl Trop Dis. 2014;20(1):26.
Hamzianpour N, Chan DL. Thromboelastographic assessment of the contribution of platelets and clotting proteases to the hypercoagulable state of dogs with immune-mediated hemolytic anemia. J Vet Emerg Crit Care. 2016;26(2):295-299.
Lim MY, Ataga KI, Key NS. Hemostatic abnormalities in sickle cell disease. Curr Opin Hematol. 2013;20(5):472-477.
de Souza GR, Hounkpe BW, Fiusa MM, et al. Tissue factor-dependent coagulation activation by heme: a thromboelastometry study. PLoS One. 2017;12(4):e0176505.
Morishita E. Diagnosis and treatment of microangiopathic hemolytic anemia. Rinsho Ketsueki. 2015;56(7):795-806.
Harahsheh Y, Ho K. Viscoelastic point-of-care testing to guide transfusion and antithrombotic therapy in perioperative and critically ill patients: are all parameters created equal? Anaesth Intensive Care. 2016;44(1):11.
Gong H, Shi C, Zhou Z, et al. Evaluating hypercoagulability in new-onset systemic lupus erythematosus patients using thromboelastography. J Clin Lab Anal. 2019;34(5):e23157.
Li Z, Xiao J, Song H, et al. Evaluation of coagulation disorders by thromboelastography in children with systemic lupus erythematosus. Lupus. 2019;28(2):181-188.
Al-Homood IA. Thrombosis in systemic lupus erythematosus: a review article. ISRN Rheumatol. 2012;2012:428269.
Aviña-Zubieta JA, Vostretsova K, De Vera MA, Sayre EC, Choi HK. The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: a general population-based study. Semin Arthritis Rheum. 2015;45(2):195-201.
Chung WS, Lin CL, Chang SN, Lu CC, Kao CH. Systemic lupus erythematosus increases the risks of deep vein thrombosis and pulmonary embolism: a nationwide cohort study. J Thromb Haemost. 2014;12(4):452-458.
Owaidah TM, Qurashi FH, Al Nounou RM, et al. Single center review of clinicopathological characterization in 77 patients with positive lupus anticoagulant antibodies. Hematology. 2003;8(4):249-257.
Harnett M, Kodali BS. Thromboelastography® assessment of coagulation status in parturients with lupus anticoagulant receiving heparin therapy. Int J Obstet Anesth. 2006;15(2):177.
Harnett M, McElrath T. Autoimmune disease. In: Datta S, Hepner DL, editors. Anesthetic and Obstetric Management of High-Risk Pregnancy. New York: Springer, 2004; p. 265-277.
Sarabi ZS, Chang E, Bobba R, et al. Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. Arthrit Care Res. 2005;53(4):609-612.
Collins K, Balasubramaniam K, Viswanathan G, et al. Assessment of blood clot formation and platelet receptor function ex vivo in patients with primary Sjögren's syndrome. BMJ Open. 2013;3(5):e002739.
Türk SM, Cansu DÜ, Teke HÜ, et al. Can we predict thrombotic tendency in rheumatoid arthritis? A thromboelastographic analysis (with ROTEM). Clin Rheumatol. 2018;37(9):2341-2349.
Ogdie A, Kay McGill N, Shin DB, et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J. 2018;39(39):3608-3614.
Page MJ, Bester J, Pretorius E. The inflammatory effects of TNF-α and complement component 3 on coagulation. Sci Rep. 2018;8(1):1-9.
Monzón Manzano E, Fernandez-Bello I, Justo Sanz R, et al. Prothrombotic state, platelet activation and netosis in systemic lupus erythematosus. Blood. 2019;134(Suppl 1):1141.
Rabik CA, Atkinson MA, Sule S, Strouse JJ. Treatment of an acquired Factor XIII inhibitor in an adolescent with systemic lupus erythematosus and renal failure. Transfusion. 2017;57(9):2159-2163.
Fernandez Bello I, López Longo FJ, Jiménez Yuste V, Canales M, Ovalles J, Butta N. Thromboelastometry shows a prothrombotic state in systemic lupus erythematosus related to diminished fibrinolysis and microparticle-derived tissue factor. Blood. 2015;126(23):2317.
Hensch L, Kostousov V, Bruzdoski K, et al. Does rotational thromboelastometry accurately predict coagulation status in patients with lupus anticoagulant? Int J Lab Hematol. 2018;40(5):521-526.
Reddy S, Friend S, Quintana D, Lockhart EL. Early detection of lupus anticoagulant-hypoprothrombinemia syndrome by rotational thromboelastometry. Blood. 2015;126(23):4699.
Cartwright B, Bean M, Cooper J. Lupus anticoagulant, antiphospholipid syndrome and cardiac surgery. Anaesth Intensive Care. 2010;38(2):364-369.
Ma Y, Rokhsar S, Volod O. TEG-platelet mapping-guided evaluation of anti-phospholipid carrier with unusual clinical presentation and paradoxical laboratory findings. Hematol Transfus Int J. 2016;2(1):00027.
Wallace NH, Dumont A, Burns A, et al. Thromboelastography in the characterization of coagulation status in antiphospholipid syndrome. Blood. 2016;128(22):4983-4983.
Breen KA, Hunt BJ. The utility of thromboelastography (TEG) in the management of patients with isolated antiphospholipid antibodies (aPL) or primary antiphospholipid syndrome (PAPS). Blood. 2010;116(1):3179.
Huissoud C, Carrabin N, Audibert F, et al. Bedside assessment of fibrinogen level in postpartum haemorrhage by thrombelastometry. BJOG. 2009;116(8):1097-1102.
Lee ES, Narasimhan U, Kofidis T, Ti LK. Difficulties with the use of thromboelastometry in a patient with antiphospholipid syndrome undergoing cardiac surgery. J Cardiothorac Vasc. 2015;29(4):1016-1020.
Samejima Y, Kodaka M, Ichikawa J, et al. Management of a patient with antiphospholipid syndrome undergoing aortic valve replacement using the hepcon hemostasis management system plus and rotational thromboelastometry: a case report. A A Pract. 2017;8(5):100-104.
Schreiber K, Breen K, Parmar K, Rand JH, Wu X-X, Hunt BJ. The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatology. 2018;57(1):120-124.
Rezoagli E, Barzaghi N, Crowther M, Dentali F, Pomero F. Antiphospholipid syndrome during septic shock: hyper-or hypocoagulability? A case report. A A Pract. 2019;13(8):306-309.
Nguyen B, Hernandez MMM, Baldeo C, Cury J, Ferreira JA. A case-report of successful use of thromboelastography to manage anticoagulation therapy in a patient with concomitant catastrophic antiphospholipid syndrome and heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 2019;30(4):171-175.
Motohashi Y, Nakazawa T, Kojima A. Analysis of blood coagulation and fibrinolysis in rheumatoid arthritis using the urokinase activated thromboelastography. Ryumachi. 1992;32(2):123-130.
Wang X, Dang A, Lv N, Cheng N, Cheng X. Inflammation is associated with platelet coagulation function rather than enzymatic coagulation function in patients with Takayasu Arteritis. Int Heart J. 2017;58(4):589-592.
Zhu M, Xu W, Wang B-L, Su H. Hemostatic function and transfusion efficacy of apheresis platelet concentrates treated with gamma irradiation in use for thrombocytopenic patients. Transfus Med Hemother. 2014;41(3):189-196.
Chen X, Zhao Z-W, Li L, et al. Hypercoagulation and elevation of blood triglycerides are characteristics of Kawasaki disease. Lipids Health Dis. 2015;14(1):166.
Jin YJ, Li LQ. Correlation discussion of blood plasma thromboelastography values and antithrombin III level in children's Kawasaki disease. J Mod Lab Med. 2017;32(5):130-132.
Fernández-Bello I, López-Longo FJ, Arias-Salgado EG, Jiménez-Yuste V, Butta NV. Behçet's disease: new insight into the relationship between procoagulant state, endothelial activation/damage and disease activity. Orphanet J Rare Dis. 2013;8(1):81.
Kivanc BK, Gönüllü E, Akay O, et al. Why are male patients with Behçet's disease prone to thrombosis? A rotational thromboelastographic analysis. Clin Exp Rheumatol. 2018;36(6):S63-S67.
Bilge NŞY, Akay OM, Kaşifoğlu T, Kuş G, Korkmaz C. The role of hemostatic mechanisms in the development of thrombosis in Behcet's disease: an analysis by modified rotation thromboelastogram (ROTEM). Clin Rheumatol. 2013;32(12):1815-1818.
Bilge SY, Akay M, Kaşifoğlu T, Gunduz E, Kus G, Korkmaz C. FRI0238 Can thromboloelastography be a new tool to asses the risk of thrombosis in behcet's disease? Ann Rheum Dis. 2013;71(Suppl 3):394-395.
Tong CK, Jin J, Du Q. Use of thromboelastogram in venovenous extracorporeal membrane oxygenation for a patient with pulmonary hemorrhage due to microscopic polyangiitis. Case Rep Crit Care. 2019;2019:7241264.
Guo K, Ma S, Wang D, Li X, He Q. Evaluation and comparison of thromboelastography and conventional coagulation tests for blood coagulation function in children with Henoch-Schönlein purpura. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019;27(3):877-886.
Murphy EA, Mustard J. Tobacco and thrombosis. Am J Public Health Nations Health. 1966;56(7):1061-1073.
Zheng P, Chen S, Shao H. Studies on hypercoagulation state in thromboangiitis obliterans. Chin Med J. 1989;102(1):67-71.
Confino E, El-Roeiy A, Friberg J, Gleicher N. The thromboelastogram and circulating lupus anticoagulant. J Reprod Med. 1989;34(4):289-291.
Emmi G, Silvestri E, Squatrito D, et al. Thrombosis in vasculitis: from pathogenesis to treatment. Thromb J. 2015;13(1):15.
Leiba M, Seligsohn U, Sidi Y, et al. Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease. Ann Rheum Dis. 2004;63(11):1445-1449.
Butta NV, Fernández-Bello I, López-Longo FJ, Jiménez-Yuste V. Endothelial dysfunction and altered coagulation as mediators of thromboembolism in Behçet disease. Semin Thromb Hemost. 2015;41(6):621-628.
Jennette JC, Thomas DB, Falk RJ. Microscopic polyangiitis (microscopic polyarteritis). Semin Diagn Pathol. 2001;18(1):3-13.
Boros G, Gofman L, Samsik J, Nagy J, Hamori A, Deak G. Blood coagulation abnormalities in the Schönlein-Henoch syndrome in adults. Acta Med Acad Sci Hungaricae. 1979;36(2):151-166.
Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med. 2000;343(12):864-869.
Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110(17):2747-2771.
Moore HB, Barrett CD, Moore EE, et al. Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome? J Trauma Acute Care Surg. 2020;88(6):1.
Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738-1742.
Spiezia L, Boscolo A, Poletto F, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020;120(6):998-1000.
Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18(7):1747-1751.